Learn more about Zellwerk GmbH
Mass production of T cells, NK cells, MSCs under GMP compliant conditions.
Producer of a new type of highly cytotoxic NK cells and specifically activated TILs.
Contract manufacturing of immune cells for use in clinical trials.
Producer of bone marrow derived MSCs in unmet high yields.
Zellwerk produces cells as ATMP for therapeutic use in man. Until today it seems that there exist limitations to procure patients with immune cells and stem cells having identified as potent for treating cancer and many other diseases lacking effective treatment options. As main obstacles we identified that the commonly used production processes are improper for manufacturing these cells in needed quantities and functionality. In addition, the actual administrative hurdles do not convene with the risk for the affected patients, the requirements of personalized medicine are neglected. When available at all, it makes living cell therapeutics expensive.
